Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
iBio announces resignation of CEO Thomas Isett » 16:31
12/02/22
12/02
16:31
12/02/22
16:31
IBIO

iBio

$1.75 /

+0.14 (+8.70%)

iBio announced the Board…

iBio announced the Board of Directors and Thomas Isett, the company's CEO, have agreed that Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the company, effective immediately. While the company continues its search for a successor, the leadership team will report to the current Chair of the Board, William Clark.

ShowHide Related Items >><<
IBIO iBio
$1.75 /

+0.14 (+8.70%)

IBIO iBio
$1.75 /

+0.14 (+8.70%)

10/06/22 Cantor Fitzgerald
iBio downgraded to Neutral from Overweight at Cantor Fitzgerald
IBIO iBio
$1.75 /

+0.14 (+8.70%)

IBIO iBio
$1.75 /

+0.14 (+8.70%)

IBIO iBio
$1.75 /

+0.14 (+8.70%)

Over a week ago
Hot Stocks
BlackBerry expands work with AWS to elevate BlackBerry QNX software to cloud » 09:20
11/28/22
11/28
09:20
11/28/22
09:20
BB

BlackBerry

$4.83 /

+0.015 (+0.31%)

BlackBerry Limited…

BlackBerry Limited announced an extension of its use of Amazon Web Services, AWS, that will make BlackBerry QNX technology available to embedded systems developers for the first time ever in the cloud, significantly reducing time to market for their products. At AWS re:Invent 2022, BlackBerry QNX will demonstrate the company's Real Time Operating System along with its artificial intelligence data platform - BlackBerry IVY - running natively on Amazon Elastic Compute Cloud instances, powered by AWS Graviton2 processors. The BlackBerry QNX RTOS running in the cloud functions as a cloud-native developer workbench and can be used independently - or in conjunction with - BlackBerry IVY, a cloud connected automotive AI platform co-developed by BlackBerry and AWS

ShowHide Related Items >><<
BB BlackBerry
$4.83 /

+0.015 (+0.31%)

BB BlackBerry
$4.83 /

+0.015 (+0.31%)

09/28/22 TD Securities
BlackBerry price target lowered to $4.75 from $5 at TD Securities
09/28/22 Canaccord
BlackBerry price target lowered to $5 from $6 at Canaccord
08/12/22 Baird
BlackBerry initiated with a Neutral at Baird
06/24/22 TD Securities
TD Securities cuts BlackBerry target to $5 after 'low-quality' beat
BB BlackBerry
$4.83 /

+0.015 (+0.31%)

BB BlackBerry
$4.83 /

+0.015 (+0.31%)

BB BlackBerry
$4.83 /

+0.015 (+0.31%)

BB BlackBerry
$4.83 /

+0.015 (+0.31%)

On The Fly
Fly Intel: Pre-market Movers » 08:56
11/22/22
11/22
08:56
11/22/22
08:56
WBA

Walgreens Boots Alliance

$40.60 /

+0.86 (+2.16%)

, GME

GameStop

$25.17 /

-2.43 (-8.80%)

, ADI

Analog Devices

$159.23 /

-2.56 (-1.58%)

, BBY

Best Buy

$70.82 /

-1.225 (-1.70%)

, AEO

American Eagle

$13.02 /

+0.085 (+0.66%)

, MDT

Medtronic

$82.26 /

+0.98 (+1.21%)

, DLTR

Dollar Tree

$165.23 /

+1.98 (+1.21%)

, GMDA

Gamida Cell

$1.79 /

+0.02 (+1.13%)

, SCPH

scPharmaceuticals

$6.09 /

-0.235 (-3.72%)

, JACK

Jack in the Box

$84.99 /

-0.22 (-0.26%)

Check out this morning's…

ShowHide Related Items >><<
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

11/22/22 Cowen
Walgreens upgraded to Outperform on services transition at Cowen
11/22/22 Cowen
Walgreens Boots Alliance upgraded to Outperform from Market Perform at Cowen
11/18/22 JPMorgan
Walgreens Boots Alliance upgraded to Overweight from Neutral at JPMorgan
11/11/22 Deutsche Bank
Walgreens upgraded to Buy with $50 target at Deutsche Bank
GME GameStop
$25.17 /

-2.43 (-8.80%)

10/13/22 Jefferies
GameStop transferred with a Hold at Jefferies
08/16/22 B. Riley
B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell
07/22/22 Wedbush
GameStop price target lowered to $7.50 from $30 at Wedbush
05/26/22 Wedbush
Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns
ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

11/15/22 Credit Suisse
Analog Devices assumed with a Neutral at Credit Suisse
10/24/22 Barclays
Analog Devices downgraded to Equal Weight from Overweight at Barclays
10/18/22 Deutsche Bank
Analog Devices price target lowered to $155 from $170 at Deutsche Bank
10/11/22 Cowen
Cowen starts Analog Devices at Outperform, says 'built to last' beyond cycle
BBY Best Buy
$70.82 /

-1.225 (-1.70%)

10/19/22 Evercore ISI
Best Buy downgraded to In Line from Outperform at Evercore ISI
10/19/22 Evercore ISI
Best Buy downgraded to In Line from Outperform at Evercore ISI
08/31/22 Truist
Best Buy price target raised to $69 from $67 at Truist
08/31/22 DA Davidson
Best Buy price target lowered to $99 from $110 at DA Davidson
AEO American Eagle
$13.02 /

+0.085 (+0.66%)

09/16/22 JPMorgan
American Eagle price target raised to $13 from $12 at JPMorgan
09/09/22 Barclays
American Eagle price target raised to $11 from $10 at Barclays
09/08/22 Cowen
American Eagle price target lowered to $11 from $13 at Cowen
09/08/22 Citi
American Eagle price target lowered to $10 from $13 at Citi
MDT Medtronic
$82.26 /

+0.98 (+1.21%)

11/16/22 Deutsche Bank
Medtronic downgraded to Hold from Buy at Deutsche Bank
10/24/22 Piper Sandler
Medtronic spinoff an 'incremental positive' for company, says Piper Sandler
10/18/22 Barclays
Barclays starts medical devices with Positive view, Boston Scientific top pick
10/17/22 Barclays
Medtronic initiated with an Equal Weight at Barclays
DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

11/16/22 OTR Global
Dollar Tree view upgraded to Positive from Mixed at OTR Global
09/06/22 JPMorgan
Dollar Tree price target raised to $176 from $171 at JPMorgan
08/29/22 Deutsche Bank
Dollar Tree price target lowered to $163 from $185 at Deutsche Bank
08/26/22 Truist
Dollar Tree price target lowered to $168 from $178 at Truist
GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

11/15/22 Oppenheimer
Gamida Cell price target lowered to $10 from $15 at Oppenheimer
10/02/22 Piper Sandler
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7
08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

11/10/22 H.C. Wainwright
scPharmaceuticals price target raised to $18 from $15 at H.C. Wainwright
10/21/22 Jefferies
scPharmaceuticals assumed with a Buy, $14 price target at Jefferies
10/20/22 Jefferies
scPharmaceuticals assumed with a Buy at Jefferies
10/11/22 Maxim
scPharmaceuticals price target raised to $13 from $10 at Maxim
JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

11/08/22 Deutsche Bank
Jack in the Box downgraded to Hold from Buy at Deutsche Bank
09/21/22 Wolfe Research
Jack in the Box initiated with a Peer Perform at Wolfe Research
09/12/22 Wedbush
Wedbush ups Jack in the Box price target to $115, adds to Best Ideas List
08/30/22 Wedbush
Jack in the Box 'most exposed' to direct impact from AB 257, says Wedbush
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

  • 22
    Nov
  • 28
    Sep
WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

SCPH scPharmaceuticals
$6.09 /

-0.235 (-3.72%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

JACK Jack in the Box
$84.99 /

-0.22 (-0.26%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

WBA Walgreens Boots Alliance
$40.60 /

+0.86 (+2.16%)

MDT Medtronic
$82.26 /

+0.98 (+1.21%)

GME GameStop
$25.17 /

-2.43 (-8.80%)

DLTR Dollar Tree
$165.23 /

+1.98 (+1.21%)

BBY Best Buy
$70.82 /

-1.225 (-1.70%)

AEO American Eagle
$13.02 /

+0.085 (+0.66%)

ADI Analog Devices
$159.23 /

-2.56 (-1.58%)

Hot Stocks
Gamida Cell says FDA extends omidubicel's PDUFA date to May 1, 2023 » 16:53
11/21/22
11/21
16:53
11/21/22
16:53
GMDA

Gamida Cell

$1.79 /

+0.02 (+1.13%)

Gamida Cell provided an…

Gamida Cell provided an update on recent interactions with the U.S. Food and Drug Administration relating to the company's Biologics License Application for omidubicel, the company's advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant. As part of its ongoing BLA review, FDA issued an information request and viewed the data in the response as a major amendment, resulting in an extension of the omidubicel Prescription Drug User Fee Act date from January 30, 2023 to May 1, 2023. The agency also rescheduled Gamida Cell's late-cycle meeting to the first quarter of 2023. The data FDA requested were laboratory results for intermediate time points for patients enrolled in the Phase 3 study. These additional data provided by Gamida Cell to FDA are consistent with prior data submissions. "We appreciate the FDA's collaboration as they conduct their review of omidubicel," said Abigail "Abbey" Jenkins, Gamida Cell's President and Chief Executive Officer. "If approved, omidubicel will be the first and only advanced cell therapy for patients with blood cancer in need of an allogeneic stem cell transplant. We are committed to bringing this potentially transformative therapy forward as quickly as possible."

ShowHide Related Items >><<
GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

11/15/22 Oppenheimer
Gamida Cell price target lowered to $10 from $15 at Oppenheimer
10/02/22 Piper Sandler
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7
08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

  • 28
    Sep
GMDA Gamida Cell
$1.79 /

+0.02 (+1.13%)

Recommendations
Mind Medicine price target lowered to $18 from $22 at Canaccord » 07:51
11/21/22
11/21
07:51
11/21/22
07:51
MNMD

Mind Medicine

$2.70 /

-0.055 (-2.00%)

Canaccord analyst Tania…

Canaccord analyst Tania Armstrong-Whitworth lowered the firm's price target on Mind Medicine to $18 from $22 and keeps a Speculative Buy rating on the shares. The analyst said given ongoing capital constraints among biotechnology peers and considering their recent cost-cutting efforts, she has reduced her target.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

11/16/22 RBC Capital
Mind Medicine initiated with an Outperform at RBC Capital
11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

  • 28
    Sep
MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

MNMD Mind Medicine
$2.70 /

-0.055 (-2.00%)

Options
Largest borrow rate increases among liquid names » 08:45
11/18/22
11/18
08:45
11/18/22
08:45
PHUN

Phunware

$1.21 /

-0.06 (-4.74%)

, NKLA

Nikola

$2.89 /

-0.11 (-3.67%)

, MNMD

Mind Medicine

$2.75 /

-0.19 (-6.46%)

, QS

QuantumScape

$7.15 /

-0.27 (-3.64%)

, KOLD

ProShares UltraShort Bloomberg Natural Gas

$15.46 /

-0.79 (-4.86%)

, AVDL

Avadel Pharmaceuticals

$7.14 /

-0.47 (-6.18%)

, PTLO

Portillo's

$20.47 /

-0.855 (-4.01%)

, QSR

Restaurant Brands

$66.61 /

+2.84 (+4.45%)

, SKLZ

Skillz

$1.02 /

-0.05 (-4.69%)

, EWH

MSCI Hong Kong Index

$19.78 /

+0.215 (+1.10%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Phunware (PHUN) 17.26% +1.39, Nikola (NKLA) 45.43% +0.82, MindMed (MNMD) 4.64% +0.82, Quantumscape (QS) 6.65% +0.73, ProShares UltraShort DJ-UBS Natural Gas (KOLD) 6.97% +0.40, Avadel Pharmaceuticals (AVDL) 5.78% +0.23, Portillo's (PTLO) 1.90% +0.21, Restaurant Brands (QSR) 0.44% +0.19, Skillz (SKLZ) 1.22% +0.18, and iShares Hong Kong (EWH) 5.21% +0.14.

ShowHide Related Items >><<
SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

12/28/21 Roth Capital
Roth Capital keeps Buy rating on Phunware, lowers price target to $4
NKLA Nikola
$2.89 /

-0.11 (-3.67%)

11/04/22 Cowen
Nikola price target lowered to $10 from $12.50 at Cowen
11/04/22 Wedbush
Nikola price target lowered to $6 from $10 at Wedbush
09/23/22 Northland
Alta Equipment Group initiated with an Outperform at Northland
09/14/22 BTIG
Nikola upgraded to Buy from Neutral at BTIG
MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

11/16/22 RBC Capital
Mind Medicine initiated with an Outperform at RBC Capital
11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
QS QuantumScape
$7.15 /

-0.27 (-3.64%)

11/09/22 Morgan Stanley
Morgan Stanley cuts QuantumScape to Underweight after 'narrative changing' Q3
11/09/22 Morgan Stanley
QuantumScape downgraded to Underweight from Equal Weight at Morgan Stanley
09/28/22 Truist
Truist starts QuantumScape at Hold, upside limited as large volumes years away
09/28/22 Truist
QuantumScape initiated with a Hold at Truist
KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

09/29/22 Deutsche Bank
Portillo's initiated with a Hold at Deutsche Bank
08/05/22 Baird
Portillo's price target raised to $30 from $22 at Baird
08/05/22 Piper Sandler
Portillo's price target raised to $27 from $23 at Piper Sandler
06/28/22 Morgan Stanley
Portillo's initiated with an Equal Weight at Morgan Stanley
QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

11/04/22 Goldman Sachs
Restaurant Brands upgraded to Neutral from Sell at Goldman Sachs
10/20/22 Barclays
Restaurant Brands price target lowered to $65 from $68 at Barclays
10/12/22 Deutsche Bank
Restaurant Brands price target lowered to $68 from $70 at Deutsche Bank
10/10/22 OTR Global
Restaurant Brands view upgraded to Positive from Mixed at OTR Global
SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

10/12/22 Citi
Skillz price target lowered to 95c from $1.50 at Citi
10/12/22 BTIG
Skillz downgraded to Sell from Neutral at BTIG
08/31/22 Citi
Skillz price target lowered to $1.50 from $1.55 at Citi
08/04/22 Canaccord
Skillz downgraded to Hold on 'disappointing' results at Canaccord
EWH MSCI Hong Kong Index
$19.78 /

+0.215 (+1.10%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

  • 15
    Nov
  • 28
    Sep
  • 12
    Aug
QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QSR Restaurant Brands
$66.61 /

+2.84 (+4.45%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PTLO Portillo's
$20.47 /

-0.855 (-4.01%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

SKLZ Skillz
$1.02 /

-0.05 (-4.69%)

QS QuantumScape
$7.15 /

-0.27 (-3.64%)

PHUN Phunware
$1.21 /

-0.06 (-4.74%)

NKLA Nikola
$2.89 /

-0.11 (-3.67%)

MNMD Mind Medicine
$2.75 /

-0.19 (-6.46%)

KOLD ProShares UltraShort Bloomberg Natural Gas
$15.46 /

-0.79 (-4.86%)

EWH MSCI Hong Kong Index
$19.78 /

+0.215 (+1.10%)

AVDL Avadel Pharmaceuticals
$7.14 /

-0.47 (-6.18%)

Initiation
Mind Medicine initiated with an Outperform at RBC Capital » 06:40
11/16/22
11/16
06:40
11/16/22
06:40
MNMD

Mind Medicine

$2.85 /

+0.02 (+0.71%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams initiated coverage of Mind Medicine with an Outperform rating and $5 price target. The analyst states that psychedelics, including LSD - which Mind Medicine lead drug MM-120 is a formulation of - have "shown increasing potential of late in treating mental health disorders". Abrahams adds that the company is taking a prudent and thoughtful approach to clinical development and scale-up that should maximize the potential they can capitalize on early promise shown for LSD in the high unmet need generalized anxiety disorder indication.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

11/14/22 Maxim
Mind Medicine price target lowered to $8 from $22.50 at Maxim
10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

  • 28
    Sep
MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

MNMD Mind Medicine
$2.85 /

+0.02 (+0.71%)

Recommendations
Gamida Cell price target lowered to $10 from $15 at Oppenheimer » 06:13
11/15/22
11/15
06:13
11/15/22
06:13
GMDA

Gamida Cell

$1.95 /

-0.145 (-6.92%)

Oppenheimer analyst Mark…

Oppenheimer analyst Mark Breidenbach lowered the firm's price target on Gamida Cell to $10 from $15 and keeps an Outperform rating on the shares following the company's Q3 earnings and conference call. The analyst remains confident that omidubicel will receive FDA approval on or before its January 30 PDUFA date, but expects the product to face stiff competition from other graft sources upon launch. Pricing remains a key unknown that could help transplant centers and payers ascertain its cost-effectiveness relative to haplo-HSCT, which Breidenbach sees as omidubicel's primary competition. An upcoming ASH presentation suggests that omidubicel holds a slight edge over most competing grafts in terms of efficacy, safety, and long-term patient outcome-but, with uncertainty still surrounding Gamida's ex-U.S. regulatory and commercial strategy, the analyst has refined his model to focus on omidubicel's U.S. commercial potential.

ShowHide Related Items >><<
GMDA Gamida Cell
$1.95 /

-0.145 (-6.92%)

GMDA Gamida Cell
$1.95 /

-0.145 (-6.92%)

10/02/22 Piper Sandler
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7
08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
GMDA Gamida Cell
$1.95 /

-0.145 (-6.92%)

  • 28
    Sep
GMDA Gamida Cell
$1.95 /

-0.145 (-6.92%)

Recommendations
Mind Medicine price target lowered to $8 from $22.50 at Maxim » 08:32
11/14/22
11/14
08:32
11/14/22
08:32
MNMD

Mind Medicine

$2.88 /

+0.29 (+11.20%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy lowered the firm's price target on Mind Medicine to $8 from $22.50 but keeps a Buy rating on the shares. The analyst is citing the company's equity financing and dilution in reducing his price target, though he also notes that it has significantly strengthened balance sheet to reach clinical milestones on its refocused pipeline. McCarthy further notes that Mind Medicine's lead program, MM-120 in generalized anxiety disorder, is expected to report data in late 2023, and its second MM-120 program, low dose for ADHD, is also expected to report topline data in the second half of next year.

ShowHide Related Items >><<
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

10/04/22 Canaccord
Mind Medicine price target lowered to US$22 from C$60 at Canaccord
09/21/22 H.C. Wainwright
Mind Medicine target adjusted for reverse share split at H.C. Wainwright
08/30/22 Oppenheimer
Mind Medicine price target raised to $52 from $3.50 at Oppenheimer
08/25/22 Oppenheimer
Mind Medicine initiated with an Outperform at Oppenheimer
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

  • 28
    Sep
MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

MNMD Mind Medicine
$2.88 /

+0.29 (+11.20%)

Earnings
Gamida Cell reports Q3 EPS (29c), consensus (31c) » 07:07
11/14/22
11/14
07:07
11/14/22
07:07
GMDA

Gamida Cell

$2.09 /

+0.23 (+12.37%)

Net loss was $17.8M in…

Net loss was $17.8M in the third quarter compared to a net loss of $23.2M in the third quarter of 2021.

ShowHide Related Items >><<
GMDA Gamida Cell
$2.09 /

+0.23 (+12.37%)

GMDA Gamida Cell
$2.09 /

+0.23 (+12.37%)

10/02/22 Piper Sandler
Piper Sandler keeps Overweight on Gamida Cell, lowers price target to $7
08/15/22 Piper Sandler
Gamida Cell price target raised to $8 from $6 at Piper Sandler
08/10/22 H.C. Wainwright
H.C. Wainwright a buyer of Gamida Cell ahead of omidubicel PDUFA date
05/10/22 Piper Sandler
Gamida Cell price target lowered to $6 from $13 at Piper Sandler
GMDA Gamida Cell
$2.09 /

+0.23 (+12.37%)

  • 28
    Sep
GMDA Gamida Cell
$2.09 /

+0.23 (+12.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.